<p>根据 Global X Japan Co. Ltd.在最近向证券交易委员会提交的 Form 13F 文件，该公司在 2023 年第三季度将其在吉利德科学公司（NASDAQ:GILD - 免费报告）的持股比例增加了 5,517.0%。这家机构投资者在此期间额外购买了 11,034 股后，持有该生物制药公司 11,234 股股票。根据其最近的 SEC 文件，Global X Japan Co. Ltd.在吉利德科学的持股价值为 1,247,000 美元。</p>
<ul>
<li>3 家公司将大现金流转化为更大的股东收益</li>
</ul>
<p>其他几家大型投资者也最近增持或减持了在 GILD 的股份。GoalVest Advisory LLC 在第二季度将其在吉利德科学的股份增加了 7,566.7%。GoalVest Advisory LLC 目前持有 230 股该生物制药公司的股票，价值 26,000 美元，此前在上个季度购买了 227 股。Activest Wealth Management 在第一季度将其在吉利德科学的股份增加了 2,837.5%。Activest Wealth Management 目前持有 235 股该生物制药公司的股票，价值 26,000 美元，此前在此期间购买了 227 股。Harbor Asset Planning Inc.在第二季度购买了吉利德科学的新股份，价值 27,000 美元。霍华德·休斯医学研究所（Howard Hughes Medical Institute）在第二季度购买了吉利德科学的新股份，价值 30,000 美元。最后，Putney Financial Group LLC 在第二季度将其在吉利德科学的持股增加了 53.4%。Putney Financial Group LLC 目前持有 270 股该生物制药公司的股票，价值 30,000 美元，此前在上个季度额外购买了 94 股。83.67% 的股票由机构投资者持有。</p>
<p>获取 <strong>吉利德科学</strong> 的提醒：</p>
<h2>吉利德科学价格表现</h2>
<p>吉利德科学的股票在周三开盘价为 125.19 美元。该公司的 50 日简单移动平均线为 122.61 美元，200 日简单移动平均线为 116.40 美元。该公司的市值为 1553.2 亿美元，市盈率为 19.41，PEG 比率为 0.69，贝塔值为 0.32。该公司的速动比率为 1.31，流动比率为 1.45，债务股本比率为 1.03。吉利德科学公司 52 周低点为 88.57 美元，52 周高点为 128.70 美元。</p>
<ul>
<li>5 个医疗保健名称值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>吉利德科学（NASDAQ:GILD - 获取免费报告）最后一次公布季度财报是在 10 月 30 日，生物制药公司报告每股收益（EPS）为 2.47 美元，超出市场共识预期的 2.16 美元，超出幅度为 0.31 美元。吉利德科学的净利润率为 27.88%，股本回报率为 51.86%。该公司在本季度的收入为 77.7 亿美元，而分析师预期为 74.2 亿美元。去年同期，该公司每股收益为 2.02 美元。与去年同期相比，吉利德科学的收入增长了 3.0%。吉利德科学已将其 2025 财年的指导目标设定为每股收益 8.050-8.250 美元。分析师平均预计吉利德科学公司本财年的每股收益为 7.95 美元。</p>
<h2>吉利德科学宣布分红</h2>
<p>该公司还最近宣布了一项季度分红，将于 12 月 30 日（星期二）支付。12 月 15 日（星期一）登记的投资者将获得每股 0.79 美元的分红。这相当于每年 3.16 美元的分红，收益率为 2.5%。该分红的除息日为 12 月 15 日（星期一）。吉利德科学的派息比率目前为 48.99%。</p>
<h2>吉利德科学的内部买卖</h2>
<ul>
<li>3 只现金充裕的股票，当前具有高增长潜力</li>
</ul>
<p>在相关消息中，执行副总裁 Deborah H. Telman 于 11 月 12 日（星期三）出售了 53,646 股该公司的股票，交易均价为 122.85 美元，总价值为 6,590,411.10 美元。出售完成后，该执行副总裁直接持有 43,676 股公司股票，价值 5,365,596.60 美元。此次交易使其持股减少了 55.12%。该出售在向证券交易委员会的法律文件中披露，文件可通过此链接获取。此外，首席财务官 Andrew D. Dickinson 于 12 月 15 日（星期一）出售了 3,000 股公司的股票，交易均价为 122.00 美元，总交易额为 366,000.00 美元。交易完成后，首席财务官持有 153,503 股公司股票，价值约 18,727,366 美元。此次交易使其持股减少了 1.92%。该出售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士出售了 136,257 股公司股票，价值 16,723,492 美元。当前公司内部人士持有 0.27% 的股票。</p>
<h2>分析师升级和降级</h2>
<p>几位股票分析师最近对该股票进行了评论。Argus 将吉利德科学的股票目标价从 130.00 美元上调至 135.00 美元，并在 11 月 4 日的报告中给予该公司 “买入” 评级。摩根大通将吉利德科学的目标价从 145.00 美元上调至 150.00 美元，并在 10 月 31 日的研究报告中给予该公司 “增持” 评级。汇丰银行将吉利德科学的价格目标从 110.00 美元上调至 133.00 美元，并在 12 月 10 日的研究报告中给予该公司 “持有” 评级。大和资本市场将吉利德科学的股票目标价从 128.00 美元上调至 129.00 美元，并在 11 月 13 日的报告中给予该股票 “跑赢大盘” 评级。最后，罗斯柴尔德与红烧公司在 11 月 10 日的研究报告中将吉利德科学的目标价从 143.00 美元上调至 153.00 美元。两位投资分析师给予该股票 “强烈买入” 评级，二十二位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 131.54 美元。</p>
<p><strong>查看我们对 GILD 的最新分析</strong></p>
<h2>吉利德科学公司简介</h2>
<p>(免费报告)</p>
<p>吉利德科学公司成立于 1987 年，总部位于加利福尼亚州福斯特城，是一家专注于高未满足医疗需求领域的药物发现、开发和商业化的生物制药公司。该公司最初在抗病毒疗法方面建立了声誉，随后扩展到肿瘤学、细胞治疗和炎症性疾病。吉利德在全球范围内运营研究和商业组织，进行临床开发并在全球市场销售药物。</p>
<p>吉利德的产品组合以 HIV 和病毒性肝炎的抗病毒疗法为基础。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票比吉利德科学更好</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解释</li>
<li>在 1 月 1 日之前投资 1,000 美元于此股票 [不是 NVDA]</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>特朗普做了什么？？</li>
</ul>
<p><strong>想看看其他对 GILD 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取吉利德科学公司（NASDAQ:GILD - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于吉利德科学吗？</h2>
<p>在考虑吉利德科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而吉利德科学并不在名单上。</p>
<p>虽然吉利德科学目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

吉利德科学

<p>Global X Japan Co. Ltd. 在第三季度大幅增加了对吉利德科学的持股比例，增幅达到 5,517%，额外购买了 11,034 股，目前持有 11,234 股，市值为 1,247,000 美元。这一举动是机构投资者调整在吉利德科学持仓的更广泛趋势的一部分。该公司的股票表现和最近的财务结果也得到了强调，包括每股收益（EPS）为 2.47 美元，超出预期</p>

<p>Global X Japan Co. Ltd. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5,517.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,234 shares of the biopharmaceutical company's stock after acquiring an additional 11,034 shares during the period. Global X Japan Co. Ltd.'s holdings in Gilead Sciences were worth $1,247,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据 Global X Japan Co. Ltd.在最近向证券交易委员会提交的 Form 13F 文件，该公司在 2023 年第三季度将其在吉利德科学公司（NASDAQ:GILD - 免费报告）的持股比例增加了 5,517.0%。这家机构投资者在此期间额外购买了 11,034 股后，持有该生物制药公司 11,234 股股票。根据其最近的 SEC 文件，Global X Japan Co. Ltd.在吉利德科学的持股价值为 1,247,000 美元。</p>
</div><ul>
<li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家公司将大现金流转化为更大的股东收益</li>
</ul>
</div><p>Several other large investors also recently added to or reduced their stakes in GILD. GoalVest Advisory LLC increased its position in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Activest Wealth Management boosted its stake in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 227 shares during the period. Harbor Asset Planning Inc. bought a new position in Gilead Sciences during the second quarter valued at $27,000. Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences in the second quarter valued at $30,000. Finally, Putney Financial Group LLC lifted its holdings in shares of Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 94 shares during the last quarter. 83.67% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家大型投资者也最近增持或减持了在 GILD 的股份。GoalVest Advisory LLC 在第二季度将其在吉利德科学的股份增加了 7,566.7%。GoalVest Advisory LLC 目前持有 230 股该生物制药公司的股票，价值 26,000 美元，此前在上个季度购买了 227 股。Activest Wealth Management 在第一季度将其在吉利德科学的股份增加了 2,837.5%。Activest Wealth Management 目前持有 235 股该生物制药公司的股票，价值 26,000 美元，此前在此期间购买了 227 股。Harbor Asset Planning Inc.在第二季度购买了吉利德科学的新股份，价值 27,000 美元。霍华德·休斯医学研究所（Howard Hughes Medical Institute）在第二季度购买了吉利德科学的新股份，价值 30,000 美元。最后，Putney Financial Group LLC 在第二季度将其在吉利德科学的持股增加了 53.4%。Putney Financial Group LLC 目前持有 270 股该生物制药公司的股票，价值 30,000 美元，此前在上个季度额外购买了 94 股。83.67% 的股票由机构投资者持有。</p>
</div><p>Get <strong>Gilead Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>吉利德科学</strong> 的提醒：</p>
</div><h2>Gilead Sciences Price Performance</h2>
<div class="lb-trans"><h2>吉利德科学价格表现</h2>
</div><p>Gilead Sciences stock opened at $125.19 on Wednesday. The company has a fifty day simple moving average of $122.61 and a 200-day simple moving average of $116.40. The firm has a market capitalization of $155.32 billion, a price-to-earnings ratio of 19.41, a PEG ratio of 0.69 and a beta of 0.32. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70.</p>
<div class="lb-trans"><p>吉利德科学的股票在周三开盘价为 125.19 美元。该公司的 50 日简单移动平均线为 122.61 美元，200 日简单移动平均线为 116.40 美元。该公司的市值为 1553.2 亿美元，市盈率为 19.41，PEG 比率为 0.69，贝塔值为 0.32。该公司的速动比率为 1.31，流动比率为 1.45，债务股本比率为 1.03。吉利德科学公司 52 周低点为 88.57 美元，52 周高点为 128.70 美元。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个医疗保健名称值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion during the quarter, compared to analysts' expectations of $7.42 billion. During the same quarter in the prior year, the company earned $2.02 EPS. Gilead Sciences's revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>吉利德科学（NASDAQ:GILD - 获取免费报告）最后一次公布季度财报是在 10 月 30 日，生物制药公司报告每股收益（EPS）为 2.47 美元，超出市场共识预期的 2.16 美元，超出幅度为 0.31 美元。吉利德科学的净利润率为 27.88%，股本回报率为 51.86%。该公司在本季度的收入为 77.7 亿美元，而分析师预期为 74.2 亿美元。去年同期，该公司每股收益为 2.02 美元。与去年同期相比，吉利德科学的收入增长了 3.0%。吉利德科学已将其 2025 财年的指导目标设定为每股收益 8.050-8.250 美元。分析师平均预计吉利德科学公司本财年的每股收益为 7.95 美元。</p>
</div><h2>Gilead Sciences Announces Dividend</h2>
<div class="lb-trans"><h2>吉利德科学宣布分红</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences's payout ratio is presently 48.99%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度分红，将于 12 月 30 日（星期二）支付。12 月 15 日（星期一）登记的投资者将获得每股 0.79 美元的分红。这相当于每年 3.16 美元的分红，收益率为 2.5%。该分红的除息日为 12 月 15 日（星期一）。吉利德科学的派息比率目前为 48.99%。</p>
</div><h2>Insider Buying and Selling at Gilead Sciences</h2>
<div class="lb-trans"><h2>吉利德科学的内部买卖</h2>
</div><ul>
<li>3 Cash-Rich Stocks With High Growth Potential Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只现金充裕的股票，当前具有高增长潜力</li>
</ul>
</div><p>In related news, EVP Deborah H. Telman sold 53,646 shares of the business's stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the sale, the executive vice president directly owned 43,676 shares of the company's stock, valued at $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the transaction, the chief financial officer owned 153,503 shares in the company, valued at approximately $18,727,366. This trade represents a 1.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 136,257 shares of company stock valued at $16,723,492. 0.27% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Deborah H. Telman 于 11 月 12 日（星期三）出售了 53,646 股该公司的股票，交易均价为 122.85 美元，总价值为 6,590,411.10 美元。出售完成后，该执行副总裁直接持有 43,676 股公司股票，价值 5,365,596.60 美元。此次交易使其持股减少了 55.12%。该出售在向证券交易委员会的法律文件中披露，文件可通过此链接获取。此外，首席财务官 Andrew D. Dickinson 于 12 月 15 日（星期一）出售了 3,000 股公司的股票，交易均价为 122.00 美元，总交易额为 366,000.00 美元。交易完成后，首席财务官持有 153,503 股公司股票，价值约 18,727,366 美元。此次交易使其持股减少了 1.92%。该出售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士出售了 136,257 股公司股票，价值 16,723,492 美元。当前公司内部人士持有 0.27% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>Several equities analysts recently commented on the stock. Argus upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, November 4th. JPMorgan Chase &amp; Co. lifted their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, October 31st. HSBC raised their price objective on Gilead Sciences from $110.00 to $133.00 and gave the company a &#34;hold&#34; rating in a research report on Wednesday, December 10th. Daiwa Capital Markets lifted their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, November 13th. Finally, Rothschild &amp; Co Redburn boosted their price target on Gilead Sciences from $143.00 to $153.00 in a research note on Monday, November 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $131.54.</p>
<div class="lb-trans"><p>几位股票分析师最近对该股票进行了评论。Argus 将吉利德科学的股票目标价从 130.00 美元上调至 135.00 美元，并在 11 月 4 日的报告中给予该公司 “买入” 评级。摩根大通将吉利德科学的目标价从 145.00 美元上调至 150.00 美元，并在 10 月 31 日的研究报告中给予该公司 “增持” 评级。汇丰银行将吉利德科学的价格目标从 110.00 美元上调至 133.00 美元，并在 12 月 10 日的研究报告中给予该公司 “持有” 评级。大和资本市场将吉利德科学的股票目标价从 128.00 美元上调至 129.00 美元，并在 11 月 13 日的报告中给予该股票 “跑赢大盘” 评级。最后，罗斯柴尔德与红烧公司在 11 月 10 日的研究报告中将吉利德科学的目标价从 143.00 美元上调至 153.00 美元。两位投资分析师给予该股票 “强烈买入” 评级，二十二位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 131.54 美元。</p>
</div><p><strong>View Our Latest Analysis on GILD</strong></p>
<div class="lb-trans"><p><strong>查看我们对 GILD 的最新分析</strong></p>
</div><h2>Gilead Sciences Profile</h2>
<div class="lb-trans"><h2>吉利德科学公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.</p>
<div class="lb-trans"><p>吉利德科学公司成立于 1987 年，总部位于加利福尼亚州福斯特城，是一家专注于高未满足医疗需求领域的药物发现、开发和商业化的生物制药公司。该公司最初在抗病毒疗法方面建立了声誉，随后扩展到肿瘤学、细胞治疗和炎症性疾病。吉利德在全球范围内运营研究和商业组织，进行临床开发并在全球市场销售药物。</p>
</div><p>Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.</p>
<div class="lb-trans"><p>吉利德的产品组合以 HIV 和病毒性肝炎的抗病毒疗法为基础。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Gilead Sciences</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Trump Did WHAT??</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比吉利德科学更好</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解释</li>
<li>在 1 月 1 日之前投资 1,000 美元于此股票 [不是 NVDA]</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>特朗普做了什么？？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding GILD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 GILD 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取吉利德科学公司（NASDAQ:GILD - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GILD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Gilead Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于吉利德科学吗？</h2>
</div><p>Before you consider Gilead Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑吉利德科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而吉利德科学并不在名单上。</p>
</div><p>While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然吉利德科学目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Global X Japan Co. Ltd. 收购了吉利德科学公司 11,034 股股票 $GILD